Fig. 7.

Eticlopride pretreatment attenuates METH-induced loss of VMAT2 (A) and increase in GFAP immunoreactivity (B), as assessed 7 days after METH treatment. Rats received four injections of METH (7.5 mg/kg s.c. per injection; 2-h intervals) or saline vehicle (1 ml/kg s.c. per injection; 2-h intervals) and were sacrificed 7 days later. Thirty minutes before each injection, rats were pretreated with eticlopride (0.5 mg/kg i.p.) or saline vehicle (1 ml/kg i.p.). Columns represent the means and vertical lines indicate 1 S.E.M. determinations in six to eight rats. *, values different from saline-treated controls (p ≤ 0.05).